MaxCyte (MXCT) Competitors

Herald (LON:HRI) and MaxCyte (LON:MXCT) are both small-cap finance companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, community ranking, institutional ownership, earnings, valuation and dividends.

Which has more volatility and risk, HRI or MXCT?

Herald has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500. Comparatively, MaxCyte has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500.

Do institutionals & insiders believe in HRI or MXCT?

31.8% of Herald shares are owned by institutional investors. Comparatively, 70.5% of MaxCyte shares are owned by institutional investors. 5.4% of Herald shares are owned by company insiders. Comparatively, 1.5% of MaxCyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Is HRI or MXCT more profitable?

Herald has a net margin of 107.72% compared to MaxCyte's net margin of -78.37%. Herald's return on equity of 14.78% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Herald	107.72%	14.78%	9.22%
MaxCyte	-78.37%	-16.01%	-11.07%

Does the MarketBeat Community favor HRI or MXCT?

MaxCyte received 50 more outperform votes than Herald when rated by MarketBeat users. Likewise, 68.92% of users gave MaxCyte an outperform vote while only 67.76% of users gave Herald an outperform vote.

Company	Underperform	Outperform
Herald	Outperform Votes 103 67.76%	Underperform Votes 49 32.24%
MaxCyte	Outperform Votes 153 68.92%	Underperform Votes 69 31.08%

Does the media favor HRI or MXCT?

In the previous week, MaxCyte had 2 more articles in the media than Herald. MarketBeat recorded 2 mentions for MaxCyte and 0 mentions for Herald. MaxCyte's average media sentiment score of 0.00 beat Herald's score of -1.04 indicating that MaxCyte is being referred to more favorably in the news media.

Company	Overall Sentiment
Herald	Negative
MaxCyte	Neutral

Which has higher earnings and valuation, HRI or MXCT?

Herald has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than Herald, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Herald	£162.63M	6.45	£175.20M	£346.54	6.00
MaxCyte	£57.52M	5.43	-£45.08M	-£27.29	-8.68

Summary

Herald beats MaxCyte on 9 of the 15 factors compared between the two stocks.